FUTURA MEDICAL ORD 0.2P overview

Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys ® drug delivery technology currently focused on sexual health, today announces that the US Food and Drug Administration (“FDA”) has granted over the counter sale (“OTC”) Marketing Authorisation for MED3000, the Company’s breakthrough, topical gel formulation for the treatment of erectile dysfunction...

EQS-News: Futura Medical PLC Futura Medical 'on track' for launch in H1 2023 13.12.2022 / 14:08 CET/CEST The issuer is solely responsible for the content of this announcement. Contact Details Proactive Proactive UK Ltd +44 20 7989 0813 [email protected] News Source: News Direct 13.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services...

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, today announces positive results from the confirmatory Phase 3 clinical study, “FM71” for MED3000, an investigational therapy for the treatment of erectile dysfunction (“ED”). Key highlights about the FM71 study: Co-primary endpoints that were agreed to with the U.S....

All arms met all primary endpoints against baseline, showing strong efficacy, safety, and rapid speed of onset However, MED2005 did not meet primary endpoints versus placebo Based on statistically significant, results compared against baseline, Futura intends to discuss a potential medical device regulatory approval pathway with the U.S. Food and Drug Administration Newly filed patent application has potential to extend protection of DermaSys ® until 2039 GUILDFORD, England, Dec. 12, 2019...

Abstracts presented at the 20 th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA) report rapid absorption and onset of action with favorable short-term safety for female partners GUILDFORD, England, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Futura Medical plc (AIM: FUM) (the "Company"), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys ® drug delivery technology and currently focused on sexual...

VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global ......

...